ROS1
Other names: ROS1 fusion, ROS1 rearrangement
ROS1 fusion is a rare marker that can direct discussion toward specific targeted therapy categories.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Plain explanation
ROS1 is a gene that, when fused with other genes, can encourage the growth of cancer cells. This fusion is discovered through molecular examination and is usually rare.
Clinical meaning
ROS1 fusions make the category of ROS1/ALK inhibitors relevant for discussion in advanced non-small-cell lung cancer, depending on other findings and patient condition.
Testing methods
- Next-generation sequencing (NGS)
A test that reads many genes from one tumour sample to find actionable changes.
- ALK immunohistochemistry
A staining test to detect ALK protein in tumour tissue.
- FISH (fluorescence in situ hybridisation)
A test that detects changes in the number or arrangement of genetic material in tumour cells.
- Tumour tissue biopsy
Collection of tumour tissue to confirm the diagnosis and provide material for further testing.
A negative result does not always mean the marker is absent
Test sensitivity differs by sample type and method. Results need to be read together with the pathology report and clinical condition.
What needs verification
- Fusion results should be confirmed by appropriate methods, not by a single screening test.
- Does the molecular panel assay include ROS1 explicitly.
- The patient's current clinical condition, including brain involvement if any.
- Availability and financing of drugs at selected facilities.
Related drugs
- Crizotinib
ALK/ROS1/MET inhibitor
- Entrectinib
TRK/ROS1/ALK inhibitor
- Lorlatinib
Third generation ALK/ROS1 inhibitor
- Repotrectinib
New generation ROS1/TRK inhibitors
A link here means the marker is often part of considering a drug category, not a recommendation to use it.
Clinical trials
Studies mentioning this marker
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT01639508Phase 2Combination regimen
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Lung Cancer | biomarker: ROS1, MET, RET, NTRK
United States7 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT01639508Not verified
NCT06315010Phase 2Targeted therapy
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
Lung Cancer | biomarker: ROS1 | Targeted therapy
Austria, Germany, Spain17 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker ROS1, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06315010Not verified
Check options based on your result
Share the ROS1 result you have so we can explain which categories to discuss with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Lung Cancer
Cancer type
Reason: Related through a biomarker
- Newly diagnosed lung cancer
Decision situation
Reason: Related through a biomarker
- Lung cancer with spread to the brain
Decision situation
Reason: Related through a biomarker
- ROS1 fusion
Molecular alteration
Reason: Related through a biomarker
- Targeted therapy
Treatment category
Reason: Related through a biomarker
- Crizotinib
Drug
Reason: Targets this marker
To check
- Tumour tissue biopsy
Diagnostic test
Reason: Diperiksa melalui
- FISH (fluorescence in situ hybridisation)
Diagnostic test
Reason: Diperiksa melalui
- ALK immunohistochemistry
Diagnostic test
Reason: Diperiksa melalui
- Next-generation sequencing (NGS)
Diagnostic test
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.